Skip to main content

Table 3 Clinical results of external beam radiation, brachytherapy boost, and concurrent chemotherapy

From: A retrospective study of external beam radiation, neutron brachytherapy, and concurrent chemotherapy for patients with localized advanced carcinoma of the esophagus

Authors (Ref.) Montravadlet al.[[15]] Sharmaet al.[[16]] RTOG9207[[14]] Present study
No. of pts. 40 100 50 140
BT Gy/fraction 10/2 15(group 1)20(group 2)/1 15/3 8-25/2-5
Interfraction interval 2 wks 1 wks 1 wks 1 wks
Applicator diameter 1 cm NS 4-6 mm 0.9 cm
EBRT Gy/fraction 40-55 Gy/4-6 weeks 50/28 50 Gy/5 wks 50-60 Gy/5-6 wks
CT (pts) Mito C 10 mg/m2 i.v. Days 1,29; 5-FU 1000 mg/m2/day 3 4 days 5-Fu 500 mg/m2, 12 h before brachytherapy DDP 75 mg/m2 Day 1 Wk 1,5,8,11 TS) 500 mg/m2 given on days 1–14 and days 21–35, or DDP 75 mg/m2 Day 1 Wk 1,5, 5-FU 750 mg/m2/day, days 1–5, Wk 1,5
5-FU 1000 mg/m2/day 3 4 days, Wk 1,5,8,11
Fistula (%) 0% 12% 12% 2.9%
Bleeding (%) NS 4% NS 3.6%
Ulcer (%) NS 29% NS NS
Stricture (%) 23% 16% 4% 3.6%
OS(%) 3 yrs 40% 5 yrs 8%(group 1) 3 yrs 29% 5 yrs 33.4%
5 yrs 23%(group 2)
LC (%) 85% Complete response; 78% Local control NS 74% Complete response; 37% Local control 70% Complete response; 55.9% Local control
  1. RTOG: Radiation Therapy Oncology Group; EBRT: external beam radiation therapy; HDR: high-dose-rate; NS: not specified; Adenoma: adenocarcinoma; Mito C: mitomycin C; DDP: cisplatin; 5-FU: 5-fluorouracil, TS: tegafur suppositories.